Target Countries:

Central& South America, Southeast Asia

Highlights: 

1. Exclusive vaccine to prevent the most common female malignant tumor - Cervical Cancer;

2. Prevent 84.5% of cervical cancer;

3. Target for female aged 9-46 yrs;

4. WHO PQ approved;

5. More affordable price than 4-valent/9-valent HPV vaccine.

Expression System：

Escherichia coli

Formulation：

With Alum adjuvant. No preservative

Target population：

Women ages 9-45years

Schedule：

0, 1, 6 m (0, 6m for 9 -14 yrs) 

Shelf-life：

2-8℃ 36 months in application

Specific Requirements:

Deal in the related industry;
Familiar with local regulation for drug entry;
Familiar with local sales channel and market;
Active and confident in promoting the product.